2018
Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis
Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. Gastroenterology 2018, 154: 1309-1319.e7. PMID: 29305933, PMCID: PMC5880739, DOI: 10.1053/j.gastro.2017.12.024.Peer-Reviewed Original ResearchConceptsWeight loss medicationsCardiometabolic risk profileHigh-density lipoprotein cholesterolWaist circumferenceDrug AdministrationSystematic reviewRisk profileLipoprotein cholesterolHemoglobin A1cObese adultsCholesterol profileSystolic/diastolic BPCardiometabolic risk factorsNetwork Meta-AnalysisRandomized clinical trialsQuality of evidenceLow-density lipoproteinModest decreaseOutcomes of interestEffect of foodLong-term useMinimal effectLiraglutide useOrlistat useBlood pressure
2016
Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis
Dulai PS, Singh S, Marquez E, Khera R, Prokop LJ, Limburg PJ, Gupta S, Murad MH. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. The BMJ 2016, 355: i6188. PMID: 27919915, PMCID: PMC5137632, DOI: 10.1136/bmj.i6188.Peer-Reviewed Original ResearchConceptsLow-dose aspirinNon-aspirin NSAIDsMetachronous neoplasiaDose aspirinColorectal neoplasiaColorectal cancerChemoprevention agentsSystematic reviewCandidate agentCandidate chemoprevention agentsMetachronous colorectal cancerHigh-dose aspirinPrimary efficacy outcomeSerious adverse eventsEfficacy of agentsQuality of evidenceWeb of ScienceEfficacy outcomesAdverse eventsFavorable riskSafety profileBenefit profileClinical trialsGRADE criteriaSafety outcomesAssociation of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016, 315: 2424-2434. PMID: 27299618, PMCID: PMC5617638, DOI: 10.1001/jama.2016.7602.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdverse eventsClinical trialsWeight lossObese adultsHigher oddsAdverse event-related treatment discontinuationSystematic reviewSignificant excess weight lossCumulative ranking (SUCRA) probabilitiesDiscontinuation of therapyExcess weight lossProportion of patientsManagement of obesityQuality of evidenceWeight loss agentsWeb of ScienceTreatment discontinuationCochrane CENTRALPharmacological treatmentMagnitude of decreaseGRADE criteriaDrug treatmentLiraglutideMAIN OUTCOMEPlacebo participants
2015
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis
Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis. Hepatology 2015, 62: 1417-1432. PMID: 26189925, DOI: 10.1002/hep.27999.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsModerate-quality evidenceNonalcoholic steatohepatitisObeticholic acidLobular inflammationBallooning degenerationVitamin ERelative riskComparative effectivenessBiopsy-proven nonalcoholic steatohepatitisLow-quality evidenceUse of pentoxifyllineIndirect treatment comparisonFuture comparative trialsHigh-quality evidenceConfidence intervalsQuality of evidenceDistinct histological featuresRecommendations AssessmentSecondary outcomesPrimary outcomeCombination therapyFibrosis stageHistological featuresComparative trialsPharmacological interventions